Application of Bayesian statistics to support approval of intravenous belimumab in children with systemic lupus erythematosus in the United States
Authors' conclusion
This approach contributed to FDA's decision to approve belimumab as the first treatment for cSLE.
Study context
- Population
- Pediatric patients with childhood-onset SLE (cSLE) in the pediatric intravenous (IV) belimumab study, with adult phase 3 IV belimumab data borrowed
- Comparison
- IV belimumab in children with SLE
- Primary endpoint
- Treatment effect in SRI response
Methodological detailsBayesian borrowing from adult phase 3 studies, robust mixture prior (skeptical prior + meta-analysis of adult treatment effects), Trial design and conduct, endpoints, key demographic and disease characteristics and pharmacokinetics (PK) similar between pediatric and adult study populations, justifying borrowing
- Bayesian borrowing from adult phase 3 studies
- Robust mixture prior (skeptical prior + meta-analysis of adult treatment effects)
- Trial design and conduct, endpoints, key demographic and disease characteristics and PK similar between pediatric and adult study populations, justifying borrowing
Primary result
As reported in the abstract
Treatment effect in SRI response (OR)
Prior weight on adult data giving 95% CrI excluding OR of one
55% or larger
Secondary outcomes
Secondary efficacy endpoints, PK and safety
- Further supported the SLE Responder Index (SRI) results
Original publication
Application of Bayesian statistics to support approval of intravenous belimumab in children with systemic lupus erythematosus in the United States. Lupus. Published 27 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →